Q&A
Question and answer with David J. Mazzo, Ph.D., president and CEO of Æterna Zentaris
Æterna Zentaris is a biopharmaceutical company focused on endocrine therapy and oncology. Its broad pipeline encompasses products from the preclinical stage through to marketed products. The lead value driver for the company is an LHRH antagonist, cetrorelix. This compound is already marketed under the trade name Cetrotide for in vitro fertilization and is currently being studied in an extensive Phase 3 clinical development program for the treatment of benign prostatic hyperplasia (BPH).
|
|
Canada’s biotech enviroment – Our experts weigh in
To get a handle on the state of the current biotechnology industry in Canada, Bio Business consulted several company and association leaders to gain their unique perspectives. Below, our panel discusses everything from the lack of funding in the Canadian industry and the current tax environment, to human resources and talent issues most affecting their businesses.
|
|
|
|
|
|
|
Growth expected for Canadian pharmaceutical market for 2007
 The Canadian pharmaceutical market is expected to grow 6.0% to 6.5% for 2007 to $19 billion in drug store and hospital sales, according to IMS Health. Last year’s market growth was slower than the 8.4% average rate achieved from 2002 to 2006.
|
|
|
Study examines compensation and entrepreneurship in the life sciences industry
 The compensation trends of senior executives within privately-held therapeutic, diagnostic, medical device, instrumentation and platform companies were explored in a recent report by Ernst & Young; executive search firm J. Robert Scott; and the law firm WilmerHale; in collaboration with professors from Harvard Business School.
|
|
Canadian CEOs lose confidence in short-termgrowth
